Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include:
- — Reduced loss from operations by 81% vs. Q3 2022 —
SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. - Highlights include:
$5.1 million in net product sales of Phexxi® (lactic acid, citric acid and potassium bitartrate) for the third quarter of 2023 and $13.4 million year-to-date 2023. - Third quarter total operating expenses were $8.7 million for 2023, a decrease of 65% as compared with the same period last year.
- Narrowed loss from operations by 81% in the third quarter of 2023 as compared with the prior year quarter.